丝裂霉素C预防浅表性膀胱癌等离子电切术后复发  

Intravesical instillation of mitomycin C after transurethral plasmakinetic resection for the prophylaxis of superficial bladder cancer recurrence

作　　者：余新立[1] 庞健[1] 陈立新[1] 廖勇彬[1] 黄晓生[1] 吴荣海[1] 程洲平[1] 

机构地区：[1]江门市中心医院泌尿外科,广东江门529070

出　　处：《广东药学》2005年第4期72-73,共2页Guangdong Pharmaceutical Journal

摘　　要：目的探讨丝裂霉素C(MMC)预防浅表性膀胱癌等离子电切术(PKRBT)后复发的有效性。方法73例浅表性膀胱癌病人行PKBRT后即MMC 40 mg膀胱内灌注,常规MMC膀胱灌注12月。结果术后6月复发3例(4.1%),12月复发11例(15.1%),20月复发15例(20.5%)。结论MMC膀胱内灌注在PKRBT术后预防复发疗效良好。Objective To evaluate the efficacy of intravesical instillation of mitomycin C after transurethral plasmakinetie resection for the prophylaxis of superficial bladder cancer recurrence. Method A total of 73 cases of superficial bladder cancer underwent transurethral plasmakinetic resection. All the cases were treated with intravesical instillation of 40 mg mitomycin C immediately after the operation. Regular intravesical instillation of mitomycin C has been given postoperatively to all cases for 1 year. All cases were followed up for 12 to 36 months （ the mean is 24.6 months）. Result There are 3,11 , 15 cases recurred at 6,12,20 months respectively. No serious side effect and complication developed either during or after instillation in all the cases. Conclusion lntravesical instillation of mitomycin C has been effective against recurrence of superficial bladder cancer after transurethral plasmakinetic resection,with advantages of good compliance and less systemic side effects.

关 键 词：膀胱癌 丝裂霉素C 等离子电切术 

分 类 号：R969[医药卫生—药理学]